METHODS

Sampling Frame and Sample
This study uses data from four waves (1995, 2000, 2005, and 2011 ) of the National Drug Abuse Treatment System Survey (NDATSS), a nationally representative survey of substance use disorder treatment programs. We define an OAT program as a physical facility with resources dedicated specifically to treating opioid dependence through methadone. We obtained lists identifying all approved OAT programs offering methadone in the United States from the Substance Abuse and Mental Health Services Administration (SAMHSA). In 2007, SAMHSA reported 1,108 licensed methadone OAT programs, a number that had remained relatively stable since 1999; by 2011, there were 1,223 licensed methadone OAT programs. The response rate for each NDATSS wave exceeded 80 percent, varying from 86 percent in 1995 to 92 percent in 2000 (Adams 2005 ).
Data Collection, Reliability, and Validity
Program directors and clinical supervisors from participating OAT programs completed telephone surveys. Reliability and validity of the surveys were maximized using established methods, such as sending each program director a cover letter explaining the study, along with worksheets informing participants of the requested data, enabling them to consult financial and administrative records prior to the call (Groves 1988) . Extensive reliability checks were performed to signal interviewers of inconsistent or infeasible responses (e.g., percentage of patients with various demographic characteristics should sum to 100 percent). Results were further scrutinized for reliability and validity by comparing reported totals (e.g., total revenue) with the sum of reported details (e.g., revenues by source); comparing responses between directors and supervisors; and comparing responses over time if an OAT program had been repeatedly included in NDATSS samples. Results from several analyses provided support for NDATSS data reliability and validity (D'Aunno and Vaughn 1995; D'Aunno and Pollack 2002; Pollack and D'Aunno 2008) .
Dependent Variable
Methadone Dose. During each wave of the NDATSS, the clinical supervisors of each OAT program were asked to report what percentage of their outpatient methadone clients received less than 40 mg of methadone per day, between In reporting this information, clinical supervisors were also asked to think only of patients who had received the same methadone dose for at least 2 weeks. Therefore, the dependent variable measures the dosage of only those patients whose dose levels have stabilized. NDATSS interviewers were instructed to check that the reported information summed to 100 percent. To increase the accuracy of the reports, NDATSS interviewers encouraged clinical supervisors to check patient records and other data they may have at their disposal documenting methadone dosage. We used these reports from clinical supervisors to calculate the percentage of patients in each OAT program who received a low methadone dose, defined as less than 60 mg/day.
Predictor Variables
Director Characteristics. Directors reported their race, Hispanic ethnicity, and gender during the interview. Racial categories were grouped as White, African American, or "other"; with the last group including primarily Asians and American Indians. In preliminary analyses, however, we found limited differences in demographic characteristics and methadone dosage patterns between white and other race directors. These categories were thus grouped for the rest of the analysis. Director's educational attainment (less than college vs. college degree vs. higher degrees), license as a substance use disorder counselor, and age were also included in the analysis.
Program Characteristics. We controlled for a number of OAT program characteristics that have been identified as important for OAT service provision. Privately owned programs may have missions different from other program types that may influence methadone dose levels. Thus, we included a categorical variable indicating whether OAT programs were private for-profit, private not-for-profit, or publicly owned. We accounted for whether OAT programs were accredited by The Joint Commission (TJC). Some accreditation bodies, including TJC, encourage provision of evidence-based services such as higher methadone doses. We also examined whether OAT programs offer buprenorphine, to determine if this approach to treatment may be associated with methadone dose practices. We also calculated the median number of patients and staff-patient ratio. We created an indicator variable taking value 1 if an OAT program had less than one staff per patient, and 0 otherwise. The geographic locations of OAT programs were categorized as one of four U.S.
census regions (Midwest, Northeast, South, and West) to account for regional variations in methadone dosing practices.
Patient Characteristics. Patient characteristics are related to methadone dose levels (D'Aunno and Pollack 2002; Pollack and D'Aunno 2008) . We thus controlled for patients' race and ethnicity (percentage of patients who were NonHispanic African American or Hispanic) and employment status (percentage of a programs patients who are unemployed). Given that patients' age may be associated with the methadone dose prescribed, the percentage of a program's patients over the age of 40 (median age) was also calculated (Anderson and Warren 2004) .
Time Trends. Practices in OAT dosing have shifted markedly across recent years (Pollack and D'Aunno 2008) . To account for time effects, we generated dummy variables designating the year in which survey data were collected, with 1995 as the reference year.
Data Analysis
We first explored whether there was an association between methadone dosage patterns at an OAT program and each of the demographic characteristics of the OAT program director listed above. To do so, we used nonparametric Kruskal-Wallis tests. We found that patients of OAT programs led by an African American director were significantly more likely to receive low methadone doses than the patients of programs led by directors from other racial groups. We then tested whether this difference was consistently observed during each survey wave using similar nonparametric tests. Second, we described differences and trends in the characteristics of African American OAT program directors versus directors from other racial groups. We tested for differences in these characteristics by director's race using chi-squared tests for categorical variables and nonparametric tests (i.e., Kruskal-Wallis test) for continuous variables. We also tested for significant trends in director's characteristics using an extension of the Kruskal-Wallis test (Cuzick 1985) . Third, we estimated the association among program director, organizational and patient characteristics, and methadone dose levels using multivariate models. We pooled observations from 1995 to 2011 and used a generalized linear model with a logit link to model the reported proportion of patients receiving doses less than 60 mg/day. We also estimated separate generalized linear models by OAT program director race to investigate whether the patterns of association between covariates and methadone dose levels varied by race of the director.
In each model, we included a variable denoting year of NDATSS to control for time trends in the dose patterns in OAT programs. We report odds ratios (OR), 95 percent confidence intervals (CI), and p-values for each independent variable. Finally, we tested for a possible interaction between the race of an OAT program director and the proportion of African Americans among the patients of that OAT program. These analyses were designed to determine whether characteristics of program directors might account for some of the racial variations in methadone dosage observed among OAT patients. We assessed the significance of the interaction term using a Wald Test. As a small number of OAT programs were interviewed during several waves of the NDATSS between 1995 and 2011, standard errors were adjusted to account for clustering of observations within OATs. All multivariate analyses were performed with Stata Version 14 (StataCorp 2013).
RESULTS
Differences and Trends in Methadone Dosage among OAT Patients
In exploratory analyses, we found no associations between the gender, age, and licensure of an OAT program director and the methadone dose levels received by the patients of his/her OAT programs. We found that the methadone doses dispensed at an OAT program varied with the educational level of the program director. In the pooled sample, OAT programs in which the director did not have a college degree provided the highest methadone doses. This finding, however, was not consistent across survey waves: in 2011, there were no significant differences in dose levels associated with education of the director. Furthermore, there were only few program directors who did not complete a college education (10 percent). This association may thus have been driven by low sample sizes. On the other hand, there were significant differences in methadone dose levels between OAT programs led by African American directors and OAT programs led by directors from other racial groups (e.g., whites). In the pooled sample (i.e., combining all observations from 1995 to 2011), the median percentage of OAT patients receiving <60 mg methadone per day was 40 percent in programs led by an African American director versus 29 percent in other OAT programs (p = .000, see Figure 1 ). The proportion of patients receiving less than 60 mg/day declined significantly between 1995 and 2011 in all OAT programs (Figure 1 ). The differences in methadone dosage patterns between OAT programs led by an African American director and other OAT programs remained throughout the study period, however.
Differences and Trends in the Characteristics of OAT Program Directors
In the pooled sample, 20.8 percent of the directors of OAT programs were African Americans. This proportion, however, declined significantly over time, from 28.7 percent in 1995 to 16.3 percent in 2011 (Figure 2 ).
There were significant differences in demographic characteristics between African American directors and other directors (Table 1) . African Americans were less likely to be Hispanic than other directors (8.7 vs. 1.8 Notes. The pooled sample is constituted from observations of all survey rounds. The difference in median percent of patients receiving <60 mg/day of methadone over time is significant at p-value .000. Within each survey round, the difference in median percent of patients receiving <60 mg/day between patients of OAT programs with with/other race versus African American directors was significant at the p < .05 level according to a Kruskal-Wallis nonparametric test.
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HSR: Health Services Research 52:5 (October 2017) percent, p = .014). There were also marginally significant differences in the educational levels of African American versus other directors (p = .092), with African American having completed slightly more schooling than other directors. However, the proportion of African American directors without a college degree appears to have increased slightly over time (from 2.9 percent in 1995 to 13.0 percent in 2011, p = .089). The median age of both African American directors and directors from other racial groups increased significantly between 1995 and 2011. African American directors were more likely to lead private not-forprofit OAT programs than other directors (57.8 percent vs. 45.0 percent, p = .033), and they were more likely to lead OAT programs in the southern United States than other directors (32.4 percent vs. 24.4 percent, p = .048). But African Americans were less likely than other directors to lead poorly staffed OAT programs (57.8 percent vs. 78.3 percent, p = .000). African American directors and directors from other races alike increasingly worked in private for-profit OAT programs and in programs dispensing buprenorphine between 1995 and 2011. In the pooled sample, there were no differences in African American directors served patient populations who were significantly more likely to be unemployed (57.0 percent vs. 48.0 percent, p = .000) and older (51.0 percent vs. 40.0 percent, p = .000) than the populations served by other directors (Table 1) . Similarly, the populations served by OAT programs with African American directors were significantly more likely to include a high proportion of African American patients than other OAT programs (50 percent vs. 10 percent, p = .000). Over time, the proportion of OAT patients above age 40 increased significantly, whereas the proportion of African American clients declined. This was the case both in OAT programs directed by African Americans and in other OAT programs. Table 2 describes multivariate regression results for the pooled 1995-2011 data. Controlling for patient and organizational covariates, we found that OAT programs with an African American director (aOR = 1.420, p = .002) remained more likely to provide low methadone doses to their patients, relative to programs with directors from other racial groups. The results also suggest that patients of OAT programs with a director who did not have a college degree (aOR = 0.618, p = .001) were less likely to receive low methadone doses than patients of programs whose director had a college degree. OAT programs serving older patient populations were less likely to dispense lower methadone doses (aOR = 0.994, p = .014). On the other hand, OAT programs that served higher proportions of African American (aOR = 1.010, p = .000) and Hispanic (aOR = 1.006, p = .014) patients were more likely to dispense lower methadone doses.
Correlates of Low Methadone Dose among OAT Patients
There were limited differences in the association of covariates and methadone dosage between OAT programs with an African American director and programs with directors from other racial groups. Among OAT program led by an African American director, those with JCAHO certification were less likely to dispense lower methadone doses to their patients (aOR = 0.638, p = .044). This was not the case among other OAT programs. Similarly, there were significant regional differences in methadone dosage patterns among OAT programs with an African American director, whereas this was not the case for OAT programs with directors from other racial groups. In particular, OAT programs with an African American director located in the Midwest or in the West were more likely to dispense low doses of methadone to their patients than similar programs located in the Northeast.
Interactions between Characteristics of OAT Program Directors and Patient Characteristics
Finally, we tested whether the association between the race/ethnicity of OAT program directors and methadone dosage differed by characteristics of the patient population. In Figure 3 , we thus show a statistically significant interaction (p = .039) between directors' race and the percentage of African American patients among the patients of an OAT program. The increased likelihood of low methadone dosage in OAT programs with an African American director was further compounded when those programs served patient populations with higher percentages of African American patients. For example, in OAT programs with 20 percent African American patients, the difference in predicted percentage of patients receiving low methadone dose between OAT programs with a white versus African American director was 5 percentage points. This difference increased to close to 20 percentage points in programs with 80 percent of African American patients (Figure 3 ). There was no interaction between Hispanic ethnicity of patients and directors' racial or ethnic group (results not shown). There were no interactions between other characteristics of program directors (e.g., gender, education, age) and the racial/ethnic composition of the patient population.
DISCUSSION
Despite significant declines in the proportion of patients receiving low methadone doses in OAT programs since 1995, a considerable proportion of programs still did not provide the recommended minimal dose of ≥60 mg/day to (some of) their patients in 2011. We found that (1) the likelihood of low methadone dosage was greater in programs with an African American program director, (2) programs with a higher proportion of minorities (i.e., African American and/or Hispanic) among their patients were more likely to provide low methadone doses, and (3) patients in programs with a high proportion of African American patients were even more likely to receive low methadone doses in programs managed by an African American director.
There are several reasons that may explain the association between the racial group of an OAT director and methadone doses dispensed by the program s/he leads. This may be the case because African American directors have different characteristics than their counterparts from other racial groups. We found, however, that most of the demographic and professional attributes of directors did not differ by race (e.g., gender, age, licensure). African American program directors had slightly higher degrees than other directors. As programs in which directors did not have a college degree were less likely to dispense low methadone doses than other programs, educational differences between directors may explain part of our findings. Nonetheless, the differences in methadone dosage patterns between programs with African Table 2 , which also includes an interaction between the race of the director and the composition of the population of patients of an OAT. The odds ratio (OR) for the interaction terms was 1.007 and significant at p = .039. The shaded areas around each line represent the 95 percent confidence interval derived from the generalized linear model.
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American directors and other programs remained even after controlling for education in multivariate analyses. The difference in methadone doses between OAT programs may also be due to systematic differences in the characteristics of OAT programs led by African American directors versus other racial groups (e.g., ownership, certification, patient population). African Americans, thus, more frequently directed private not-for-profit OAT programs (Table 1) . Similarly, the OAT programs directed by African Americans often served more disadvantaged patient populations (e.g., more unemployed patients). However, such characteristics of the OAT programs or the patient populations they serve were not associated with methadone dose levels. On the other hand, African American directors led programs that treated patient populations with a significantly larger proportion of African Americans. As the likelihood of receiving low methadone doses was also much larger in such populations, this is likely the key factor in explaining differences in methadone dosage patterns associated with the race of the OAT program director.
There may be a number of other factors contributing to differences in methadone dosage between OAT programs, such as attitudes and beliefs about methadone as an approach to treatment. Various directors' attitudes toward methadone have been associated with provision of low methadone doses (Pollack and D'Aunno 2008) . If such attitudes are more prevalent among African American directors than among directors from other racial groups, then they may account for part of the differences in methadone dosage between OAT programs associated with director's race. These attitudes include, for example, support of abstinence orientation or opposition to syringe exchange. In addition, programs with directors who believe African American patients need treatment from staff who are either African American or educated in the history of African Americans (i.e., culturally competent treatment programs) are more likely to provide lower doses (Howard, Barrett, and Holmes 2010) . Concerns about methadone treatment as a substitute of one addiction for another, especially among African Americans, may influence dosing patterns in programs managed by African American directors (Stancliff et al. 2002) . Unfortunately, the NDATSS did not elicit the attitudes of directors toward methadone and other substance abuse treatment practices. There is thus a need to investigate racial differences in leadership beliefs and attitudes about methadone use, dosing guidelines, and how these perceptions may adversely affect care practices.
The methadone dosage patterns observed in OAT programs with African American directors may also be linked to dynamics among treatment program staff, particularly in organizations in which directors manage a racially diverse workforce. Unfortunately, the NDATSS also did not consistently measure the racial/ethnic composition of the staff of an OAT program. We thus could not investigate this pathway directly. Management research, however, suggests that increasing workplace diversity elicits a complex array of organizational processes (Williams and O'Reilly 1998; Mannix and Neale 2005) . Within the context of our findings, a more diverse managerial and clinical workforce may allow more interactions between staff from several racial/ethnic groups. During these interactions, and through observation, staff may gain a heightened awareness of variations in their treatment practices. They may ultimately develop more empirically informed or practice recommended approaches of providing care. On the other hand, a more diverse workforce may also lead to more conflicts and less cooperation between staff (Williams and O'Reilly 1998; Jackson, Joshi, and Erhardt 2003; Bell et al. 2011) . Staff members may be less likely to share information and both clinical and administrative decision making may become fragmented. Organizational dysfunction accentuates the uncertainty associated with clinical decisions and increases the likelihood that providers will rely on stereotypes when making treatment choices (van Ryn and Fu 2003) . This may subsequently lead to lower than recommended methadone dosage, particularly for racial and ethnic minority patients. Although the IOM recommends increasing workplace diversity to improve the health of minority patients, the effects of this recommendation depend on the organizational processes that may unfold in increasingly diverse health care organizations (Phillips and Loyd 2006; van Knippenberg and Schippers 2007) . Further research is needed to examine the influence of staff diversity in health care organizations on treatment practices and outcomes.
Our finding that OAT programs serving high proportions of minority patients dispense lower methadone doses is in line with extensive literature on variations in access to and quality of care in the U.S. health care system (Smedley, Stith, and Nelson 2003; National Healthcare Quality & Disparities Reports 2014) . Although African Americans and Hispanics are disproportionately affected by substance use disorders, they often receive substandard health care and have worse outcomes relative to whites (Arndt, Acion, and White 2013) . OAT programs in predominately minority communities tend to offer lower quality and fewer treatment services (Acevedo et al. 2012) . Minority patients are less likely to receive care that matches their need (Schmidt et al., 2007; Marsh et al. 2009 ). Other correlates of variation in the treatment of substance use disorders by race/ethnicity include geographic access and health insurance status (Cummings et al. 2013 ). There are also persistent negative perceptions of methadone among racial and ethnic minority injection drug users, including beliefs that methadone has considerable negative health consequences and that patients should prioritize the discontinuation of methadone (Zaller et al. 2009 ). African Americans perceived physical effects of methadone (i.e., brittle bones and dependence on methadone) might be a deterrent for methadone (Schwartz et al. 2008) . Shame and stigma associated with methadone treatment among some Hispanic patients has also been shown to influence attitudes toward methadone for treatment (Reynoso-Vallejo et al. 2008) . Minority patients with less favorable perceptions of methadone may hence be less likely to accept methadone, especially at higher doses. Interventions that increase patient awareness and acceptability of OAT, especially among minorities, may thus be important to addressing racial and ethnic variations in methadone dose patterns.
Improving on prior studies, we also found that the likelihood of African American patients receiving low methadone doses was compounded by the program director being of African American race. The pathways through which such an interaction between directors' race and the racial composition of the patient population emerges are likely multifarious. Perhaps director race/ethnicity is a proxy for other unobserved socioeconomic factors, such as characteristics of the neighborhood where the treatment center is located. It may also reflect other attributes of the patient population. On the other hand, director race/ethnicity may be a distinct construct and predisposes the director to specific perceptions regarding African American patients. These perceptions may consequently influence decision making about treatment practices. African American directors may provide lower methadone doses to African American patients because they perceive that a different approach to treatment may be more beneficial for this population group. In such cases, lower doses are provided in combination with other treatment modalities (e.g., behavioral and other therapeutic interventions) (Howard 2003) . However, these directors may also provide lower doses to African American patients because of negative perceptions concerning black patients (Holt 2007) . Additional studies are needed to better understand why methadone dosage is particularly low in OAT programs that serve a high percentage of African American patients and whose director is also African American. Qualitative methods, in particular, could help shed some light on the complex mechanisms underlying the relationships among race of client, race of director, and methadone dose levels.
LIMITATIONS
We have already mentioned several of the limitations that affect our analysis, for example, lack of data on directors' attitudes and on staff racial/ethnic diversity. There are several additional limitations. First, there may be a number of other factors, such as director's experience in addiction health services or sources of information about effective practices and treatment recommendations, which can influence dose levels. Patient involvement in treatment decisions, patient mix, and dose levels based on patient need may also have a role. Unfortunately, these factors were not systematically documented by the NDATSS. Second, even though we found variations in methadone dosage associated with the race of director and the racial composition of the patient population, our results do not address whether there are racial/ethnic disparities at the individual level within an OAT treatment program. Such investigation would help understand the mechanisms through which the association between director's race and methadone dose levels emerges. It would, however, require patient-level data, which are not collected by the NDATSS. Third, our analyses were limited by low sample size. For example, we could not investigate whether there were significant time trends in the association between organizational practices and the race of the OAT program director. Similarly, we could not assess the impact of some demographic characteristics of directors such as their educational level in more detail. Future research should use more recent data and a larger sample size to examine a broader range of managerial, patient, and external factors (e.g., state policies, treatment regulations) that may influence dose levels provided by OAT programs. Fourth, our analyses only documented methadone dosage patterns, without considering patient outcomes such as treatment completion. Finally, we could not make any causal inferences about the effects of directors' race on patient outcomes from this analysis. This is so because our data are drawn from repeated cross-sections and only include a limited number of OAT programs that were followed over time. We, thus, could not ascertain whether recruiting a director of a specific racial group led to subsequent changes in treatment practices and methadone dosage levels. Future research on the impact of managerial factors should be based on more detailed panel datasets. They should also explore the use of randomized trials to evaluate the effectiveness of managerial interventions to improve patient outcomes. Such interventions may include, for example, improved access to sources of information about evidence-based practices in OAT programs, as well as changes in recruitment and training practices for OAT program directors.
CONCLUSION
Few studies have examined associations between the characteristics of the director and treatment practices of a health care organization. We showed that in OAT programs, the race of the program director was significantly associated with the adoption of suboptimal treatment practices (i.e., low methadone dosage), particularly in programs that serve a large proportion of minority patients. Further research should investigate the causal pathways through which race and other characteristics of OAT program directors affect methadone dosage. This could then lead to new managerial interventions designed to improve treatment practices and patient outcomes in OAT programs.
